| News

Lonza manufactures coronavirus vaccine for Moderna

17.11.2020

Lonza plans to start production of Moderna’s coronavirus vaccine in Switzerland before the end of the year. Moderna published the initial results from a phase 3 study, according to which the vaccine candidate is 94.5 percent effective. Moderna opened a subsidiary in Basel to drive forward the production of the vaccine from there.

Moderna is a vaccine manufacturer working on a COVID-19 vaccine. Based in Massachusetts, the manufacturer has founded a subsidiary in Basel. According to Basel Area Business & Innovation in August, Moderna was “vigorously supported” when setting up the new company, Moderna Switzerland GmbH. The support ranged from questions on setting up a company and work permits with regard to the COVID-19 situation to suggestions about office spaces. The successful establishment of a subsidiary by Moderna will highlight the attractiveness of the Basel area’s biotech ecosystem.

Lonza will manufacture the mRNA-1273 vaccine for Moderna. According to a press release from the Basel-based pharmaceutical supplier, large-scale production started at its American factory in Portsmouth, NH at the end of September. Production is also set to start at Lonza’s factory in Visp in the canton of Wallis before the end of the year. Lonza plans to manufacture 400 million vaccine doses per year at Visp. Back in May, Moderna and Lonza agreed on a total manufacturing output of 1 billion doses per year.

Moderna has recently published the initial results from a phase 3 study, according to which the vaccine candidate is 94.5 percent effective.

Lonza is also working on the development of a coronavirus vaccine with another American manufacturer: Humanigen. Cameron Durrant, CEO of Humanigen, is quoted in a press release on the collaboration, saying: “This collaboration with Lonza, a global manufacturing leader with expertise in technology transfer and an established track record of working with regulatory bodies for approved and commercialized products, comes at a crucial time to meet production demand for COVID-19 therapeutics this winter.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
1 2 3 48

Do you have a question? We'd like to hear from you.